Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study

P. Calzavara-Pinton, J. Čelakovská, H. Lapeere, G. Holzer, M. Al-Ahmad, CY. Chu, SM. Ferrucci, Y. Kataoka, M. Rossi, DS. Fomina, WH. Chung, T. Tzellos, AC. Fougerousse, J. Wu, M. Ardeleanu, ZE. Ozturk

. 2023 ; 40 (12) : 5366-5382. [pub] 20231006

Jazyk angličtina Země Spojené státy americké

Typ dokumentu pozorovací studie, audiovizuální média, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000443

INTRODUCTION: Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting. METHODS: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information. We report baseline characteristics, comorbidities and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed. RESULTS: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean [standard deviation]) percent body surface area affected (44.8 [24.42]), Eczema Area and Severity Index total score (24.8 [12.95]), SCORing Atopic Dermatitis total score (60.5 [16.34]), Patient-Oriented Eczema Measure total score (19.7 [6.37]) and Dermatology Life Quality Index total score (13.7 [7.02]). Overall, 741 (77.8%) patients reported ≥ 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7%]), asthma (323 [33.9%]), food allergy (294 [30.9%]) or another allergy (274 [28.8%]). In the previous 12 months, 310 (32.6%) patients had received systemic non-steroidal immunosuppressants and 169 (17.8%) systemic corticosteroids; 449 (47.2%) had received topical corticosteroids, most commonly potent topical corticosteroids; 141 (14.8%) had received topical calcineurin inhibitors and 32 (3.4%) ultraviolet therapy. Most (713 [74.9%]) patients started dupilumab because of prior treatment failure. CONCLUSION: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic and non-systemic AD treatments. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03992417. Video Abstract.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000443
003      
CZ-PrNML
005      
20240213093203.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12325-023-02644-5 $2 doi
035    __
$a (PubMed)37801232
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Calzavara-Pinton, Piergiacomo $u Dermatology Department, University of Brescia, Brescia, Italy. piergiacomo.calzavarapinton@unibs.it
245    10
$a Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study / $c P. Calzavara-Pinton, J. Čelakovská, H. Lapeere, G. Holzer, M. Al-Ahmad, CY. Chu, SM. Ferrucci, Y. Kataoka, M. Rossi, DS. Fomina, WH. Chung, T. Tzellos, AC. Fougerousse, J. Wu, M. Ardeleanu, ZE. Ozturk
520    9_
$a INTRODUCTION: Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting. METHODS: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information. We report baseline characteristics, comorbidities and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed. RESULTS: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean [standard deviation]) percent body surface area affected (44.8 [24.42]), Eczema Area and Severity Index total score (24.8 [12.95]), SCORing Atopic Dermatitis total score (60.5 [16.34]), Patient-Oriented Eczema Measure total score (19.7 [6.37]) and Dermatology Life Quality Index total score (13.7 [7.02]). Overall, 741 (77.8%) patients reported ≥ 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7%]), asthma (323 [33.9%]), food allergy (294 [30.9%]) or another allergy (274 [28.8%]). In the previous 12 months, 310 (32.6%) patients had received systemic non-steroidal immunosuppressants and 169 (17.8%) systemic corticosteroids; 449 (47.2%) had received topical corticosteroids, most commonly potent topical corticosteroids; 141 (14.8%) had received topical calcineurin inhibitors and 32 (3.4%) ultraviolet therapy. Most (713 [74.9%]) patients started dupilumab because of prior treatment failure. CONCLUSION: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic and non-systemic AD treatments. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03992417. Video Abstract.
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    _2
$a mladiství $7 D000293
650    12
$a atopická dermatitida $x farmakoterapie $x epidemiologie $7 D003876
650    _2
$a kvalita života $7 D011788
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    _2
$a hormony kůry nadledvin $x terapeutické užití $7 D000305
650    12
$a ekzém $7 D004485
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a dvojitá slepá metoda $7 D004311
655    _2
$a pozorovací studie $7 D064888
655    _2
$a audiovizuální média $7 D059040
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Čelakovská, Jarmila $u Department of Dermatology and Venereology, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, Czech Republic
700    1_
$a Lapeere, Hilde $u Department of Dermatology, Ghent University Hospital, Ghent, Belgium
700    1_
$a Holzer, Gregor $u Sozialmedizinisches Zentrum Ost-Donauspital, Vienna, Austria
700    1_
$a Al-Ahmad, Mona $u Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait
700    1_
$a Chu, Chia-Yu $u Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
700    1_
$a Ferrucci, Silvia M $u Unit of Dermatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
700    1_
$a Kataoka, Yoko $u Department of Dermatology, Osaka Habikino Medical Center, Osaka, Japan
700    1_
$a Rossi, Mariateresa $u Dermatology Department, University of Brescia, Brescia, Italy
700    1_
$a Fomina, Daria S $u City Clinical Hospital No. 52, Moscow, Russian Federation $u I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
700    1_
$a Chung, Wen-Hung $u Chang Gung Memorial Hospital, Linkou and Taipei, Taiwan
700    1_
$a Tzellos, Thrasyvoulos $u Institute of Clinical Medicine, Arctic University of Norway, Tromsø, Norway
700    1_
$a Fougerousse, Anne-Claire $u Military Teaching Hospital Begin, Saint Mandé, Paris, France $u ResoEczema, Paris, France
700    1_
$a Wu, Jiangming $u Sanofi, Bridgewater, NJ, USA
700    1_
$a Ardeleanu, Marius $u Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA
700    1_
$a Ozturk, Zafer E $u Sanofi, Cambridge, MA, USA
773    0_
$w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 40, č. 12 (2023), s. 5366-5382
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37801232 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093200 $b ABA008
999    __
$a ok $b bmc $g 2049234 $s 1210137
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 40 $c 12 $d 5366-5382 $e 20231006 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace